Neuroscientific Biopharmaceuticals (ASX:NSB) ROCE % : -14.13% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Neuroscientific Biopharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Neuroscientific Biopharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2024 was -14.13%.

Neuroscientific Biopharmaceuticals ROCE % Historical Data

The historical data trend for Neuroscientific Biopharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuroscientific Biopharmaceuticals ROCE % Chart

Neuroscientific Biopharmaceuticals Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

ROCE %

Get a 7-Day Free Trial

-65.79

-34.82

-104.40

-20.84

6.65

Neuroscientific Biopharmaceuticals Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial								-151.15	110.61	-57.43	67.90	-14.13

Neuroscientific Biopharmaceuticals ROCE % Calculation

Neuroscientific Biopharmaceuticals's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	0.334	/	( ( (5.291 - 0.597)	+	(5.436 - 0.086) )	/ 2 )
	=	0.334	/	( (4.694	+	5.35)	/ 2 )
	=	0.334	/	5.022
	=	6.65 %

Neuroscientific Biopharmaceuticals's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	-0.73	/	( ( (5.436 - 0.086)	+	(5.009 - 0.026) )	/ 2 )
	=	-0.73	/	( ( 5.35	+	4.983 )	/ 2 )
	=	-0.73	/	5.1665
	=	-14.13 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

Neuroscientific Biopharmaceuticals (ASX:NSB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Neuroscientific Biopharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Neuroscientific Biopharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuroscientific Biopharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuroscientific Biopharmaceuticals Ltd (ASX:NSB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

a Street, Suite 5, Cottesloe, Perth, WA, AUS, 6011

Website

https://www.neuroscientific.com

Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies.

Neuroscientific Biopharmaceuticals Headlines

No Headlines